Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Metis TechBio CoFRA:RO9 +7.99%17 Debt-to-Equity is 0.13 as of Dec. 2025. GuruFocus rates FRA:RO9 with a GF Score™ of 17/100. The stock has 1 warning sign investors should review. Among 968 Biotechnology companies, Metis TechBio Co ranks better than 55.06% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Metis TechBio Co's Debt-to-Equity or its related term are showing as below:
FRA:RO9'
s Debt-to-Equity Range Over the Past 10 Years
Min: -7.44 Med: -0.1 Max: 0.13
Current: 0.13
During the past 4 years, the highest Debt-to-Equity Ratio of Metis TechBio Co was 0.13. The lowest was -7.44. And the median was -0.10.
FRA:RO9's Debt-to-Equity is ranked better than 55.06% of 968
companies
in the Biotechnology industry
Industry Median: 0.16
vs FRA:RO9: 0.13
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Metis TechBio Co Debt-to-Equity Related Terms
Metis TechBio Co Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Metis TechBio Co's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Metis TechBio Co Debt-to-Equity Chart
Metis TechBio Co Annual Data
Trend
Dec22
Dec23
Dec24
Dec25
Debt-to-Equity
-7.44
-0.13
-0.07
0.13
Metis TechBio Co Quarterly Data
Dec22
Dec23
Dec24
Sep25
Dec25
Debt-to-Equity
-7.44
-0.13
-0.07
0.11
0.13
FRA:RO9 vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, Metis TechBio Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Metis TechBio Co Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Metis TechBio Co's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Metis TechBio Co's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Metis TechBio Co (FRA:RO9) has a Debt-to-Equity of 0.13 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Metis TechBio Co and its competitors. According to the industry distribution chart, Metis TechBio Co ranks #435 out of 968 companies in the Biotechnology industry, placing it in the top 44.9%.
Is Metis TechBio Co's Debt-to-Equity too high?
Metis TechBio Co's current Debt-to-Equity is 0.13. The Biotechnology industry median Debt-to-Equity is 0.16. Metis TechBio Co's value of 0.13 is 18.8% below this industry median. Based on the distribution chart, Metis TechBio Co ranks #435 out of 968 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Metis TechBio Co has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Metis TechBio Co's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Metis TechBio Co ranks #435 out of 968 companies for Debt-to-Equity. This puts Metis TechBio Co in the upper half of its industry. The industry median Debt-to-Equity is 0.16. Metis TechBio Co's value of 0.13 is 18.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 968 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Metis TechBio Co's current Debt-to-Equity of 0.13 is 18.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Metis TechBio Co and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Metis TechBio Co's current Debt-to-Equity is 0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metis TechBio Co stock overvalued right now?
Metis TechBio Co (FRA:RO9) has a current Debt-to-Equity of 0.13. The current Debt-to-Equity is 0.13 and 18.8% below the Biotechnology industry median of 0.16. Metis TechBio Co's overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Metis TechBio Co (FRA:RO9), the current Debt-to-Equity is 0.13 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Metis TechBio Co Ltd is an investment holding company. The company and its subsidiaries are principally engaged in AI-empowered nanomaterial innovation for the delivery and application of active agents across all carbon-based life forms. Its technology platform, NanoForge, comprises a set of integrated tools, including a lipid library, AI models, an AI agent (METiS), quantum chemistry and molecular dynamics simulations, and high-throughput screening platforms. The company has developed three solution platforms (AiTEM, AiLNP, and AiRNA) designed to simulate, predict, and interpret nanoscale interactions, enabling the rational design, optimization, and validation of nanomaterials and their associated payloads.
17GF Score
Get the complete analysis for FRA:RO9
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RO9 has been successfully added to your 
